BUZZ-Vir jumps on positive data from early-stage trials for tumor treatments

Drug developer Vir Biotechnology's VIR.O shares rise 33.2% to $10.50 premarket

Co says its drugs VIR-5818 and VIR-5500 showed compelling response in patients with various solid tumors during early-stage trials

Says VIR-5818 showed tumor shrinkage in 50% of patients with various HER2 positive cancers

HER2 is a protein that stimulates quick growth of cancer cells

VIR says all 12 patients who took VIR-5500 showed a decline in prostate-specific antigen levels, which indicate the presence of prostate cancer

Up to last close, stock down 25.6% in the last 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))